Nanomedicine News

RSS

MMA Champion Partners with ABL to Develop Nano Silver-Based, Wound Dressing Gel

Every athlete, no matter what level they compete at, knows that training and practice weigh heavily on the outcome of each competition. But more importantly, are they aware of the rising incidence of incapacitating ‘superbugs’ that live in locker rooms, health clubs, gymnasiums and schools? Microorganisms such as E. coli, Staph, and MRSA can put a serious damper on a person’s ability to perform well in a sport, especially if they are not managed properly. These types of infections can and will spread to others, while possibly leading to season and/or career-ending injuries.

9 Mar 2015

Northwestern University to Establish Ronald and JoAnne Willens Center for Nano Oncology

A new $10 million gift from Ronald and JoAnne Willens to Northwestern University’s International Institute for Nanotechnology (IIN) will establish an interdisciplinary research center that will use advances in nanotechnology to develop new cancer treatments. It will be one of the first centers of its kind in the country.

9 Mar 2015

Aura Biosciences Secures Funding to Further Develop Novel Viral Nanoparticle Technology

Aura Biosciences, a biotech company developing highly tumor-targeted breakthrough therapies for rare cancers, has secured a $21M Series B round of funding. The financing was led by Advent Life Sciences, with participation from new investors, Chiesi Ventures, Ysios Capital, and Alexandria Venture Investments.

6 Mar 2015

Scientists Develop Nanocarriers Capable of Transporting Medicines Specifically to Disease Site

Nanoparticles are extremely small particles that can be modified for a variety of uses in the medical field. For example, nanoparticles can be engineered to be able to transport medicines specifically to the disease site while not interfering with healthy body parts.

6 Mar 2015

Cerulean and GOG Foundation Partner to Conduct CRLX101-Paclitaxel Combination Clinical Trial for Relapsed Ovarian Cancer

Cerulean Pharma Inc., a leader in Dynamic Tumor Targeting™, today announced it has signed a clinical research agreement with the GOG Foundation Inc. to conduct an open-label Phase 1b clinical trial of its lead product candidate, CRLX101, in combination with weekly paclitaxel in patients with relapsed ovarian cancer.

4 Mar 2015

Next-Generation Magnetic Nanoparticles to Treat Deep-Seated Tumors

Thanks to the work of an interdisciplinary team of researchers at the Dartmouth Center of Nanotechnology Excellence, funded by the National Institutes of Health, the next-generation magnetic nanoparticles (MNPs) may soon be treating deep-seated and difficult-to-reach tumors within the human body.

4 Mar 2015

Novel Nanodevice Blocks Drug-Resistant Genes and Then Releases Cancer Drugs

Chemotherapy often shrinks tumors at first, but as cancer cells become resistant to drug treatment, tumors can grow back. A new nanodevice developed by MIT researchers can help overcome that by first blocking the gene that confers drug resistance, then launching a new chemotherapy attack against the disarmed tumors.

From Massachusetts Institute of Technology 3 Mar 2015

EC Approves Celgene’s ABRAXANE for First-Line Treatment of Non-Small Cell Lung Cancer

Celgene International Sàrl, a wholly owned subsidiary of Celgene Corporation, today announced that the European Commission (EC) has approved ABRAXANE® (paclitaxel formulated as albumin-bound nanoparticles, or nab-paclitaxel) in combination with carboplatin for the first-line treatment of non-small cell lung cancer in adult patients who are not candidates for potentially curative surgery and/or radiation therapy.

3 Mar 2015

New Insight Report on Cancer Nanomedicine Market

Research and Markets has announced the addition of the "Cancer Nanomedicine Market & Pipeline Insight 2015" report to their offering.

26 Feb 2015

University of Manchester Scientists Selectively Target and Neutralize Cancer Stem Cells Using Graphene

University of Manchester scientists have used graphene to target and neutralise cancer stem cells while not harming other cells.

26 Feb 2015

Nanomedicine News

MMA Champion Partners with ABL to Develop Nano Silver-Based, Wound Dressing Gel

Northwestern University to Establish Ronald and JoAnne Willens Center for Nano Oncology

Aura Biosciences Secures Funding to Further Develop Novel Viral Nanoparticle Technology

Scientists Develop Nanocarriers Capable of Transporting Medicines Specifically to Disease Site

Cerulean and GOG Foundation Partner to Conduct CRLX101-Paclitaxel Combination Clinical Trial for Relapsed Ovarian Cancer

Next-Generation Magnetic Nanoparticles to Treat Deep-Seated Tumors

Novel Nanodevice Blocks Drug-Resistant Genes and Then Releases Cancer Drugs

EC Approves Celgene’s ABRAXANE for First-Line Treatment of Non-Small Cell Lung Cancer

New Insight Report on Cancer Nanomedicine Market

University of Manchester Scientists Selectively Target and Neutralize Cancer Stem Cells Using Graphene

Enhanced Antibacterial Polylactic Acid-Curcumin Nanofibers for Wound Dressings

Gold Nanoparticles to Restore Vision in Retinal Disorders

Levidian and Zentek Seek to Establish Graphene-Integrated Filter Manufacturing Facility in the Middle East to Advance Cleaner, Safer Air

Scalable Method for Porous Graphene Membranes for CO2 Capture

Biochar-Modified Titanium Dioxide Nanocomposites for Enhanced Water Treatment

Overcoming Nanogold Production Challenges

Electrospinning and the Future of Nanotechnology

How Electrospinning is Shaping the Future of Nanotechnology

Sponsored Content

Utilizing Back-Gate Voltage Biases for 2D Materials

Resistivity Metrology for Sputtered ITO Thin Films

How Plasma Cleaning Technology Tackles Hydrocarbon Contamination

Optimizing EV Lubricants with Electrified Tribotesting